Hamza Suria - Dec 20, 2021 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Signature
/s/ Eric Loumeau, Attorney-in-Fact
Stock symbol
ANAB
Transactions as of
Dec 20, 2021
Transactions value $
-$1,262,516
Form type
4
Date filed
12/22/2021, 05:42 PM
Previous filing
Nov 17, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $41K +36.6K +53.42% $1.12* 105K Dec 20, 2021 Direct
transaction ANAB Common Stock Sale -$416K -11.9K -11.32% $34.89 93.3K Dec 20, 2021 Direct F1, F2
transaction ANAB Common Stock Sale -$687K -19.2K -20.58% $35.75 74.1K Dec 20, 2021 Direct F1, F3
transaction ANAB Common Stock Sale -$201K -5.52K -7.45% $36.40 68.6K Dec 20, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (Right to Buy) Options Exercise $0 -36.6K -100% $0.00* 0 Dec 20, 2021 Common Stock 36.6K $1.12 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F5 The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022.
F6 In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.